Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. The company was founded in 2005 and is based in Pasadena, California.

Lixte Biotechnology Holdings, Inc.

Lixte Biotechnology Holdings, Inc. (Lixte) is a clinical-stage public (LIXT) pharmaceutical company dedicated to discovering drugs for more effective treatments for cancer. Lixte has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. The current drug portfolio includes inhibitors of protein phosphatases that are critical to cell division and DNA damage repair and inhibitors of protein deacetylases that regulate pathways of gene expression and protein degradation. 

The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general as well as radiation therapy making them potentially useful for the treatment of many, if not all, cancers in combination with existing standard chemotherapy regimens and the evolving targeted cytotoxic therapies of personalized cancer medicine. The lead compound LB-100 is in Phase I trial and has the potential to be first-in-class. 

The deacetylase inhibitors have anti-cancer activity and in model systems correct enzymes deficiencies underlying several inborn metabolic diseases including Gaucher and von Hippel-Lindau disease and neurofibromatosis type 2. 

Lixte's cancer drug development strategy has led to the discovery of novel compounds with the potential to be therapeutically useful against several other important but seemingly disparate diseases. The phosphatase inhibitors are in pre-clinical development for reducing the extent of tissue damage following stroke, heart attack, and septic shock; and, the deacetylase inhibitors for prevention and treatment of neurodegenerative diseases, traumatic brain injury, and topically for fungal dermatitis .

This morning we announced that our lead clinical compound, LB-100, can kill cancer cells through hyper-stimulation of cell proliferation signals in pre-clinical models, according to a report published in Cold Spring Harbor Laboratory's bioRxiv titled, “Paradoxical activation of oncogenic signaling as a cancer treatment strategy.” Click the graphic to read comments from the report's co-author and Lixte's CEO, John Kovach, MD, on how the data suggests that paradoxical activation of oncogenic signaling can result in tumor suppressive resistance. #LB100 #cancer #hyperstimulation #Lixte #BixRxiv 

https://lnkd.in/gNnwzmns

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
net income	-1.37M -	-2.77M 101.20%	-2.85M 3.11%	-2.13M 25.15%	-1.81M 15.29%	-2.13M 17.96%	-2.44M 14.40%	-3.26M 33.79%	-6.73M 106.08%	-6.31M 6.18%	-5.09M 19.41%
depreciation and amortization
deferred income tax
stock based compensation	119.25K -	946.17K 693.44%	549.70K 41.90%	287.16K 47.76%	70.69K 75.38%	785.61K 1,011.27%	748.65K 4.70%	1.25M 67.15%	2.60M 107.69%	1.55M 40.51%
change in working capital	75.49K -	-252.64K 434.67%	-84.49K 66.56%	170.13K 301.36%	325.54K 91.35%	-163.52K 150.23%	17.54K 110.73%	-117.88K 772.07%	-13.44K 88.60%	154.76K 1,251.39%	-73.98K 147.80%
accounts receivables			-200K -	200K 200%			-14.37K -	14.37K 200%
inventory			12.59K -	35.12K 178.93%			14.37K -	-14.37K 200%
accounts payables	27.36K -	14.76K 46.05%	36.54K 147.57%	519 98.58%	152.44K 29,271.68%	-116.82K 176.64%	-51.66K 55.78%	46.74K 190.48%	35.67K 23.68%	3.80K 89.35%	-73.98K 2,047.25%
other working capital	48.13K -	-267.40K 655.56%	66.38K 124.82%	-65.51K 198.69%	173.10K 364.23%	-46.70K 126.98%	69.20K 248.20%	-164.62K 337.89%	-49.11K 70.17%	150.96K 407.36%	73.98K 51.00%
other non cash items		437.11K -	205.77K 52.92%								867.74K -
net cash provided by operating activities	-1.18M -	-1.64M 38.59%	-2.18M 33.36%	-1.68M 23.09%	-1.41M 15.81%	-1.51M 7.00%	-1.67M 10.79%	-2.13M 27.31%	-4.14M 94.37%	-4.61M 11.32%	-4.29M 6.91%
investments in property plant and equipment
acquisitions net										5.14M -
purchases of investments		-207.56K -
sales maturities of investments				104.09K -							3.14M -
other investing activites	-1 -		109.60K -
net cash used for investing activites	-1 -	-207.56K 20,756,300%	109.60K 152.80%	104.09K 5.03%						5.14M -	3.14M 38.98%
debt repayment
common stock issued			1.75M -	1.75M 0%	2.50M 42.86%	4.50M 80%		4.60M -	3.69M 19.82%	5.14M 39.34%
common stock repurchased
dividends paid			-2K -	-2K 0%
other financing activites	2.50M -	1.41M 43.54%	304.39K 78.45%		18K -	-21.70K 220.57%		4.60K -	207.63K 4,411.98%		3.14M -
net cash used provided by financing activities	2.50M -	1.41M 43.54%	2.05M 45.30%	1.75M 14.83%	2.52M 44.05%	4.48M 77.85%		4.60M -	3.90M 15.31%	5.14M 31.92%	3.14M 38.86%
effect of forex changes on cash	-2.50M -									-5.14M -
net change in cash	-1.18M -	-430.61K 63.51%	-19.13K 95.56%	174.65K 1,012.95%	1.11M 533.17%	2.97M 168.33%	-1.67M 156.42%	2.47M 247.56%	-245.52K 109.94%	529.65K 315.72%	1.99M 275.18%
cash at beginning of period	1.66M -	475.02K 71.30%	44.41K 90.65%	25.28K 43.07%	199.93K 690.83%	1.31M 553.11%	4.27M 227.25%	2.60M 39.18%	5.07M 95.06%	4.82M 4.84%	5.35M 10.98%
cash at end of period	475.02K -	44.41K 90.65%	25.28K 43.07%	199.93K 690.83%	1.31M 553.11%	4.27M 227.25%	2.60M 39.18%	5.07M 95.06%	4.82M 4.84%	5.35M 10.98%	7.34M 37.12%
operating cash flow	-1.18M -	-1.64M 38.59%	-2.18M 33.36%	-1.68M 23.09%	-1.41M 15.81%	-1.51M 7.00%	-1.67M 10.79%	-2.13M 27.31%	-4.14M 94.37%	-4.61M 11.32%	-4.29M 6.91%
capital expenditure
free cash flow	-1.18M -	-1.64M 38.59%	-2.18M 33.36%	-1.68M 23.09%	-1.41M 15.81%	-1.51M 7.00%	-1.67M 10.79%	-2.13M 27.31%	-4.14M 94.37%	-4.61M 11.32%	-4.29M 6.91%

NASDAQ:LIXT

Lixte Biotechnology Holdings, Inc.

Last Close

2.31

26/07 20:00

Market Cap

5.08M

Beta: −0.30

Volume Today

9.06K

Avg: 443.13K

PE Ratio

−0.76

PFCF: −1.01

Preview